

David C Fisher

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/916869/publications.pdf>

Version: 2024-02-01

58
papers

1,862
citations

430874

18
h-index

276875

41
g-index

58
all docs

58
docs citations

58
times ranked

3836
citing authors

#	ARTICLE	IF	CITATIONS
1	Immune Reconstitution following High-Dose Chemotherapy and Autologous Stem Cell Transplantation with or without Pembrolizumab Maintenance Therapy in Patients with Lymphoma. Transplantation and Cellular Therapy, 2022, 28, 32.e1-32.e10.	1.2	7
2	Venetoclax plus dose-adjusted R-EPOCH for Richter syndrome. Blood, 2022, 139, 686-689.	1.4	29
3	Topical tofacitinib for the management of lymphocytic variant hypereosinophilic syndrome with cutaneous involvement. Dermatologic Therapy, 2022, 35, e15518.	1.7	1
4	A phase 1b/2 study of duvelisib in combination with FCR (DFCR) for frontline therapy for younger CLL patients. Leukemia, 2021, 35, 1064-1072.	7.2	25
5	Response to brentuximab vedotin versus physician's choice by CD30 expression and large cell transformation status in patients with mycosis fungoides: An ALCANZA sub-analysis. European Journal of Cancer, 2021, 148, 411-421.	2.8	27
6	Randomized phase 3 ALCANZA study of brentuximab vedotin vs physician's choice in cutaneous T-cell lymphoma: final data. Blood Advances, 2021, 5, 5098-5106.	5.2	46
7	Acalabrutinib, venetoclax, and obinutuzumab as frontline treatment for chronic lymphocytic leukaemia: a single-arm, open-label, phase 2 study. Lancet Oncology, The, 2021, 22, 1391-1402.	10.7	53
8	Targeting constitutively active STAT3 in chronic lymphocytic leukemia: A clinical trial of the STAT3 inhibitor pyrimethamine with pharmacodynamic analyses. American Journal of Hematology, 2021, 96, E95-E98.	4.1	17
9	A T cell inflammatory phenotype is associated with autoimmune toxicity of the PI3K inhibitor duvelisib in chronic lymphocytic leukemia. Leukemia, 2021, , .	7.2	14
10	Rituximab/bendamustine and rituximab/cytarabine induction therapy for transplant-eligible mantle cell lymphoma. Blood Advances, 2020, 4, 858-867.	5.2	40
11	Perioperative Serum 25-Hydroxyvitamin D Levels as a Predictor of Postoperative Opioid Use and Opioid Use Disorder: a Cohort Study. Journal of General Internal Medicine, 2020, 35, 2545-2552.	2.6	7
12	Updated Results from a Phase I/II Study of Duvelisib and Venetoclax in Patients with Relapsed or Refractory CLL/SLL or Richter's Syndrome. Blood, 2020, 136, 46-47.	1.4	13
13	Updated Safety and Efficacy Results from a Phase 2 Study of Acalabrutinib, Venetoclax and Obinutuzumab (AVO) for Frontline Treatment of Chronic Lymphocytic Leukemia (CLL). Blood, 2020, 136, 20-21.	1.4	16
14	Prognostic Value of Circulating Tumor DNA (ctDNA) in Autologous Stem Cell Graft and Post-Transplant Plasma Samples Among Patients with Diffuse Large B-Cell Lymphoma. Blood, 2020, 136, 22-23.	1.4	4
15	Interim Positron Emission Tomography (iPET) Assessed Using Deauville Score for Patients with Follicular Lymphoma Receiving First-Line Chemoimmunotherapy. Blood, 2020, 136, 37-38.	1.4	1
16	Ibrutinib plus fludarabine, cyclophosphamide, and rituximab as initial treatment for younger patients with chronic lymphocytic leukaemia: a single-arm, multicentre, phase 2 trial. Lancet Haematology, the, 2019, 6, e419-e428.	4.6	60
17	PD-1 blockade with pembrolizumab for classical Hodgkin lymphoma after autologous stem cell transplantation. Blood, 2019, 134, 22-29.	1.4	129
18	Umbralisib in combination with ibrutinib in patients with relapsed or refractory chronic lymphocytic leukaemia or mantle cell lymphoma: a multicentre phase 1b study. Lancet Haematology, the, 2019, 6, e38-e47.	4.6	98

#	ARTICLE	IF	CITATIONS
19	Ofatumumab plus high dose methylprednisolone followed by ofatumumab plus alemtuzumab to achieve maximal cyto reduction prior to allogeneic transplantation for 17p deleted or TP53 mutated chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2019, 60, 1312-1315.	1.3	3
20	A Phase I Study of Duvelisib and Venetoclax in Patients with Relapsed or Refractory CLL / SLL. <i>Blood</i> , 2019, 134, 1763-1763.	1.4	6
21	Preliminary Safety and Efficacy Results from a Phase 2 Study of Acalabrutinib, Venetoclax and Obinutuzumab in Patients with Previously Untreated Chronic Lymphocytic Leukemia (CLL). <i>Blood</i> , 2019, 134, 32-32.	1.4	28
22	High-throughput sequencing of the T cell receptor β gene identifies aggressive early-stage mycosis fungoides. <i>Science Translational Medicine</i> , 2018, 10, .	12.4	92
23	Rituximab/Bendamustine and Rituximab/Cytarabine (RB/RC) Induction Chemotherapy for Transplant-Eligible Patients with Mantle Cell Lymphoma: A Pooled Analysis of Two Phase 2 Clinical Trials and Off-Trial Experience. <i>Blood</i> , 2018, 132, 145-145.	1.4	5
24	PD-1 Blockade with Pembrolizumab for Classical Hodgkin Lymphoma after Autologous Stem Cell Transplantation. <i>Blood</i> , 2018, 132, 1650-1650.	1.4	2
25	PD-1 Blockade for Diffuse Large B-Cell Lymphoma after Autologous Stem Cell Transplantation. <i>Blood</i> , 2018, 132, 706-706.	1.4	3
26	The Combination of Duvelisib, a PI3K- $\hat{\gamma}$, $\hat{\beta}$ Inhibitor, and Romidepsin Is Highly Active in Relapsed/Refractory Peripheral T-Cell Lymphoma with Low Rates of Transaminitis: Results of Parallel Multicenter, Phase 1 Combination Studies with Expansion Cohorts. <i>Blood</i> , 2018, 132, 683-683.	1.4	28
27	Superior Clinical Benefit of Brentuximab Vedotin in Mycosis Fungoides Versus Physician's Choice Irrespective of CD30 Level or Large Cell Transformation Status in the Phase 3 ALCANZA Study. <i>Blood</i> , 2018, 132, 1646-1646.	1.4	0
28	Clonal Hematopoiesis Associated With Adverse Outcomes After Autologous Stem-Cell Transplantation for Lymphoma. <i>Journal of Clinical Oncology</i> , 2017, 35, 1598-1605.	1.6	339
29	Stem cell-released oncolytic herpes simplex virus has therapeutic efficacy in brain metastatic melanomas. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017, 114, E6157-E6165.	7.1	90
30	SCDT-26. STEM CELL LOADED ONCOLYTIC VIRUSES TRACK AND KILL METASTATIC BRAIN TUMORS. <i>Neuro-Oncology</i> , 2017, 19, vi270-vi270.	1.2	0
31	Whole-blood RNA transcript-based models can predict clinical response in two large independent clinical studies of patients with advanced melanoma treated with the checkpoint inhibitor, tremelimumab. , 2017, 5, 67.		28
32	The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice. <i>Cancer Cell</i> , 2016, 29, 574-586.	16.8	227
33	Idelalisib given front-line for treatment of chronic lymphocytic leukemia causes frequent immune-mediated hepatotoxicity. <i>Blood</i> , 2016, 128, 195-203.	1.4	259
34	Histopathologic spectrum of hypersensitivity reactions associated with anti-CD52 therapy (alemtuzumab). <i>Journal of Cutaneous Pathology</i> , 2016, 43, 989-993.	1.3	10
35	A phase 2 study of Rituximab + Bendamustine and Rituximab + Cytarabine for transplant-eligible patients with mantle cell lymphoma. <i>British Journal of Haematology</i> , 2016, 173, 89-95.	2.5	51
36	T-Cell Lymphoma Patient-Derived Xenografts and Newly Developed Cell Lines Recapitulate Aspects of Disease Biology and Represent Novel Tools for Preclinical Drug Development. <i>Blood</i> , 2016, 128, 3015-3015.	1.4	1

#	ARTICLE	IF	CITATIONS
37	Initial Results of a Multicenter, Phase II Study of Ibrutinib Plus FCR (iFCR) As Frontline Therapy for Younger CLL Patients. <i>Blood</i> , 2016, 128, 3243-3243.	1.4	15
38	TGR-1202 in Combination with Ibrutinib in Patients with Relapsed or Refractory CLL or MCL: Preliminary Results of a Multicenter Phase I/Ib Study. <i>Blood</i> , 2016, 128, 641-641.	1.4	10
39	Sequencing-Based Detection of Circulating Tumor DNA in the Autologous Stem Cell Grafts of Patients with Diffuse Large B-Cell Lymphoma Undergoing Hematopoietic Stem Cell Transplantation. <i>Blood</i> , 2015, 126, 3156-3156.	1.4	2
40	Preliminary Results of a Phase Ib Study of Duvelisib in Combination with FCR (dFCR) in Previously Untreated, Younger Patients with CLL. <i>Blood</i> , 2015, 126, 4158-4158.	1.4	9
41	A Phase II Study of Ofatumumab-High Dose Methylprednisolone Followed By Ofatumumab-Alemtuzumab in 17p Deleted or TP53 Mutated CLL. <i>Blood</i> , 2015, 126, 4159-4159.	1.4	1
42	Double Expressing (MYC/BCL2) and Double-Hit Diffuse Large B-Cell Lymphomas Have Inferior Survival Following Autologous Stem Cell Transplantation. <i>Blood</i> , 2015, 126, 522-522.	1.4	3
43	B and T-Cell Lymphoma Patient-Derived Xenografts Recapitulate Aspects of Disease Biology and Progression and Represent Novel Tools for Preclinical Drug Development. <i>Blood</i> , 2015, 126, 4001-4001.	1.4	0
44	Blood mRNA Expression Profiling Predicts Survival in Patients Treated with Tremelimumab. <i>Clinical Cancer Research</i> , 2014, 20, 3310-3318.	7.0	29
45	Thyroid lymphoma on a background of Hashimoto's thyroiditis: PET/CT appearances. <i>Clinical Imaging</i> , 2014, 38, 864-867.	1.5	3
46	Ofatumumab As Initial Therapy For Indolent B Cell Lymphomas: A Phase II Trial. <i>Blood</i> , 2013, 122, 3062-3062.	1.4	14
47	Prognostic Factors for Patients with Diffuse Large B Cell Lymphoma and Transformed Indolent Lymphoma Undergoing Autologous Stem Cell Transplantation in the PET Era. <i>Blood</i> , 2012, 120, 1980-1980.	1.4	0
48	Everolimus in Combination with Rituximab Induces Complete Responses in Heavily Pretreated Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2011, 118, 1635-1635.	1.4	3
49	Obatoclox in Combination with Fludarabine and Rituximab (FR) Is Well-Tolerated and Shows Promising Clinical Activity in Relapsed CLL/SLL. <i>Blood</i> , 2011, 118, 2865-2865.	1.4	3
50	Increased Dose Rituximab Followed by Maintenance Rituximab As Initial Therapy for Indolent B Cell Lymphomas: A Phase II Trial,. <i>Blood</i> , 2011, 118, 3716-3716.	1.4	0
51	Reply to J. Mehta. <i>Journal of Clinical Oncology</i> , 2009, 27, e139-e140.	1.6	0
52	A Phase 2 Study of Fludarabine and Rituximab for the Treatment of Marginal Zone Lymphomas.. <i>Blood</i> , 2007, 110, 1358-1358.	1.4	2
53	Phase II Trial of the Oral mTOR Inhibitor RAD001 (Everolimus) in Relapsed and/or Refractory Waldenstrom Macroglobulinemia: Preliminary Results.. <i>Blood</i> , 2007, 110, 4496-4496.	1.4	2
54	Prospective Evaluation of FDG-PET Imaging of Treatment Response in Relapsed Follicular Lymphoma.. <i>Blood</i> , 2007, 110, 2331-2331.	1.4	6

#	ARTICLE	IF	CITATIONS
55	Non-Myeloablative Allogeneic Transplantation for Hodgkinâ€™s and Non-Hodgkinâ€™s Lymphoma: Evidence for a Graft-Versus-Lymphoma Effect and Relevance of Chimerism.. Blood, 2007, 110, 3041-3041.	1.4	0
56	Sirolimus and Tacrolimus as Graft-vs.-Host Disease Prophylaxis in Allogeneic Stem Cell Transplantation: The Dana-Farber Cancer Institute Experience.. Blood, 2004, 104, 1227-1227.	1.4	0
57	Prevention of Acute GVHD with Sirolimus Does Not Abrogate the Risk of Chronic GVHD.. Blood, 2004, 104, 3317-3317.	1.4	0
58	Unusual Presentations of Malignancy. Journal of Clinical Oncology, 2001, 19, 3291-3293.	1.6	1